Today’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and vTV Therapeutics
NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Inovio Pharmaceuticals saw its shares climb over 14% by the close on Tuesday as traders digested positive data that was published in Clinical Cancer Research. Shares of vTv Therapeutics were also soaring yesterday, in fact the stock saw triple digit gains, but there was no rhyme nor reason for the sudden breakout.
RDI Initiates Coverage on:
Inovio Pharmaceuticals, Inc
https://rdinvesting.com/news/?ticker=INO
vTv Therapeutics Inc.
https://rdinvesting.com/news/?ticker=VTVT
Inovio Pharmaceuticals, Inc. shares closed up 14.21% on about 4.8 million shares traded on Tuesday. Average trading volume for the stock is just around 900,000 shares. The price jump came after Wall Street learned that the clinical-stage biotech had announced the publication of results in Clinical Cancer Research, a major cancer journal, from a study of MEDI0457. The data focused on one patient in the study who experienced full remission from head and neck cancer after being treated by MEDI0457 followed by treatment with a PD-1 checkpoint inhibitor. The complete response by the one patient has been sustained for more than two years. MEDI0457 was licensed in 2015 to MedImmune, an arm of AstraZeneca. CEO of Inovio, Dr. J. Joseph Kim, remarked, "We are buoyed by the study as it lends support to all of our HPV and oncology programs. These data demonstrated that Inovio’s technology based in MEDI0457 can generate durable HPV16/18 antigen-specific peripheral and tumor immune responses. The study supports our belief that this approach may be used as a complementary strategy to PD-1/PD-L1 inhibition in HPV-associated head and neck and other types of cancer to improve therapeutic outcomes. Inovio is collaborating with MedImmune (w/ MEDI0457) as well as Genentech and Regeneron (w/ INO-5401) in efficacy trials coupling Inovio’s DNA-based cancer immunotherapies with checkpoint inhibitors designed to increase response rates with data expected in 2019.”
Access RDI’s Inovio Pharmaceuticals, Inc Research Report at:
https://rdinvesting.com/news/?ticker=INO
vTv Therapeutics Inc. shares were up nearly 159% yesterday on about 21 million shares traded despite any news from the company nor catalyst to explain the jump. It was roughly two months ago that the biotech company reported its second quarter results. The company reported loss of $0.29 per share for the quarter, which trailed behind the consensus estimates of loss per share of $0.25 by $0.04. vTv Therapeutics reported revenue of $2.47 million, while analysts had expected revenue of $2.46 million. It was revealed at the end of last month that major shareholder Ronald O. Perelman had acquired 1,879,699 shares of vTv Therapeutics stock in a transaction on Thursday, September 6th. The company discovers, develops, and sells orally administered small molecule drug candidates worldwide and has a drug candidate called azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Access RDI’s vTv Therapeutics Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VTVT
Our Actionable Research on Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and vTv Therapeutics Inc. (NASDAQ: VTVT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com